Eagle Health Investments LP Invests $30.54 Million in Scholar Rock Holding Corporation $SRRK

Eagle Health Investments LP bought a new stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 555,272 shares of the company’s stock, valued at approximately $30,540,000. Scholar Rock makes up about 5.1% of Eagle Health Investments LP’s investment portfolio, making the stock its 7th biggest holding. Eagle Health Investments LP owned 0.46% of Scholar Rock at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Jennison Associates LLC increased its holdings in shares of Scholar Rock by 74.0% in the 4th quarter. Jennison Associates LLC now owns 2,795,188 shares of the company’s stock worth $123,128,000 after buying an additional 1,188,676 shares during the last quarter. iA Global Asset Management Inc. bought a new position in shares of Scholar Rock in the 4th quarter valued at about $5,430,000. Geode Capital Management LLC lifted its holdings in shares of Scholar Rock by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 2,034,024 shares of the company’s stock valued at $89,616,000 after acquiring an additional 79,214 shares during the last quarter. Norges Bank purchased a new position in Scholar Rock in the fourth quarter worth about $91,603,000. Finally, First Turn Management LLC purchased a new position in Scholar Rock in the fourth quarter worth about $20,251,000. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Price Performance

SRRK opened at $56.51 on Thursday. The business has a fifty day moving average of $51.40 and a 200 day moving average of $48.34. The stock has a market cap of $6.88 billion, a P/E ratio of -16.38 and a beta of 0.69. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77. Scholar Rock Holding Corporation has a 52-week low of $27.07 and a 52-week high of $58.49.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.84). During the same period in the previous year, the business posted ($0.98) earnings per share. As a group, sell-side analysts anticipate that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on SRRK shares. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, June 18th. BMO Capital Markets reiterated an “outperform” rating and issued a $76.00 target price on shares of Scholar Rock in a report on Friday, August 7th. HC Wainwright reissued a “buy” rating and set a $65.00 target price on shares of Scholar Rock in a research report on Monday, August 10th. Barclays increased their price target on Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, Wedbush restated an “outperform” rating and issued a $58.00 price target on shares of Scholar Rock in a research report on Monday, August 10th. Four analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $57.71.

Insider Transactions at Scholar Rock

In other Scholar Rock news, Director Jeffrey S. Flier sold 3,053 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total value of $164,495.64. Following the completion of the sale, the director directly owned 27,856 shares of the company’s stock, valued at $1,500,881.28. The trade was a 9.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Joshua Reed sold 3,053 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total transaction of $164,068.22. Following the completion of the transaction, the director owned 19,518 shares in the company, valued at $1,048,897.32. This represents a 13.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 17,149 shares of company stock valued at $923,108. Company insiders own 10.30% of the company’s stock.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).